arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT US Healthcare & Life Sciences Summit 2017

Facing the Tidal Wave: Risk and Opportunity in a Shifting Healthcare Landscape

New York |
Speakers include:
Dieter	 Weinand

Dieter Weinand


Tanisha Carino

Tanisha Carino


David Blumenthal

David Blumenthal

The Commonwealth Fund


The US healthcare industry is experiencing a period of profound change. A new Republican- led government is in place with a popular mandate to ‘repeal and replace’ many of the reforms that have transformed the industry in recent years, and healthcare leaders will need to adjust strategies to the wave of new polices and regulations emanating from Washington. At a more grass roots, operational level, however, new payment and delivery models are fundamentally reshaping how the industry conducts its business. Traditional boundaries between healthcare and life sciences businesses and professions are being dismantled. Meanwhile, new science and technology-from drones to the microbiome and robotics-are expanding the realm of opportunities for the industry.  How will the future unfold?

The FT US Healthcare and Life Sciences Summit, now its sixth successful year, will bring together industry leaders from across the healthcare and life sciences continuum to explore the major transformations ahead.

Topics for discussion will include:

  • US Healthcare reform: risk and opportunity in the new health economy
  • How will value transform the business of health?
  • Addressing social determinants of health-the next big healthcare challenge
  • Skills and leadership: What will the healthcare workforce of the future look like?
  • Is the future of healthcare virtual? Prospects for home care and telehealth
  • Beyond genomics: the next big Innovations on the frontiers of science, technology and medicine

Click here to view videos and photographs from the  FT US Healthcare & Life Sciences Summit 2016. 

fallback Add to my Calendar 05/18/2017 08:00:0005/18/2017 17:20:00trueFT US Healthcare & Life Sciences Summit 2017The US healthcare industry is experiencing a period of profound change. A new Republican- led government is in place with a popular mandate to ‘repeal and replace’ many of the reforms that have transformed the industry in recent years, and healthcare leaders will need to adjust strategies to the wave of new polices and regulations emanating from Washington. At a more grass roots, operational level, however, new payment and delivery models are fundamentally reshaping how the industry conducts its business. Traditional boundaries between healthcare and life sciences businesses and professions are being dismantled. Meanwhile, new science and technology-from drones to the microbiome and robotics-are expanding the realm of opportunities for the industry.  How will the future unfold?The FT US Healthcare and Life Sciences Summit, now its sixth successful year, will bring together industry leaders from across the healthcare and life sciences continuum to explore the major transformations ahead.Topics for discussion will include:US Healthcare reform: risk and opportunity in the new health economyHow will value transform the business of health?Addressing social determinants of health-the next big healthcare challengeSkills and leadership: What will the healthcare workforce of the future look like?Is the future of healthcare virtual? Prospects for home care and telehealthBeyond genomics: the next big Innovations on the frontiers of science, technology and medicineClick  here to view videos and photographs from the  FT US Healthcare & Life Sciences Summit 2016. FT-US-Healthcare-&-Life-Sciences-Summit-201729784a2551e5e1b56db4df2b4b97a30dMM/DD/YYYY

Event Photos

Please see photos from the event here 

USHC photos


Hear from past attendees:


"This summit has become the Davos or The TED conference for healthcare and life sciences.The best minds having meaningful discussions." - Lawrence Gottlieb, President & CEO, Hudson Valley Economic Development Corporation

"Best array of speakers, balanced panels with provocative discussions. The day seemed to go by in a snap. Didn't want it to end. Wanted to learn more." - James Lebret, Physician, NYU Medical Centre

"Subject matter experts - depth and breadth of knowledge across entire eco-system, FT does an excellent job with the selection of speakers and conducting the panel discussions." - Anonymous


Speakers (35)

Dieter	 Weinand

Dieter Weinand

Member of the Board of Management and President, Pharmaceuticals

Dieter Weinand has been a member of the Board of Management and President of the Pharmaceuticals Division of Bayer AG, headquartered in Berlin, since January 2016. He joined Bayer in August 2014 as Head of the Pharmaceuticals Division.In the course of a career stretching back over 25 years, he has held various positions in commercial, operational and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer and Bristol-Myers Squibb. Mr Weinand earned an MS in Pharmacology and Toxicology from Long Island University, New York, and a BA in biology from Concordia College, New York.

Tanisha Carino

Tanisha Carino

Vice President, US Public Policy

Tanisha Carino serves as Vice President, US Public Policy at GlaxoSmithKline, which is committed to helping people do more, feel better and live longer. In her role, Dr Carino promotes public policies in the best interest of patients and the public’s health.  She joined the company from Avalere Health, a strategic health care advisory company, where she oversaw advisory and research services for the nation’s leading life sciences companies as Executive Vice President. Dr Carino brings over 15 years of experience in consulting, management, health policy and strategy development across government, industry and academia. She is a recognized thought leader in the evolving US regulatory environment, market access and commercial trends, as well as health technology and evidence-based medicine. Dr Carino has a PhD in Health Policy from Johns Hopkins University and is a Fulbright scholar. She serves as an associate faculty member in the Johns Hopkins Bloomberg School of Public Health and is a board member of Bread for the City in Washington, District of Columbia.

David Blumenthal

David Blumenthal

President and CEO
The Commonwealth Fund

David Blumenthal, MD, MPP became President and CEO of The Commonwealth Fund, a national healthcare philanthropy based in New York City, in January, 2013. Previously, he served as Chief Health Information and Innovation Officer at Partners Health System in Boston, MA, and was Samuel O. Thier Professor of Medicine and Professor of Health Care Policy at Massachusetts General Hospital/ Harvard Medical School. From 2009 to 2011, Dr Blumenthal was the National Coordinator for Health Information Technology under President Barack Obama. In this role he was charged with building an interoperable, private and secure nationwide health information system and supporting the widespread, meaningful use of health IT. Prior to that, Dr Blumenthal was a practicing primary care physician, Director of the Institute for Health Policy, and Professor of Medicine and Health policy at Massachusetts General Hospital/Partners Healthcare System and Harvard Medical School. As a renowned health services researcher and national authority on health IT adoption, Dr Blumenthal has authored over 250 scholarly publications, including the seminal studies on the adoption and use of health information technology in the United States. Dr Blumenthal received his undergraduate, medical and public policy degrees from Harvard University and completed his residency in internal medicine at Massachusetts General Hospital.

Robert Henkel

Robert Henkel

President and Chief Executive Officer
Ascension Health

Robert Henkel, FACHE, is the President and CEO of Ascension Health. He also serves as an Executive Vice President of Ascension. Before being appointed to his current position, he served as President, Healthcare Operations and Chief Operating Officer, and prior to 2004, he served as President of the Great Lakes and Mid-Atlantic States Operating Group at Ascension Health. Mr. Henkel has held executive positions with numerous other healthcare organizations, including the Daughters of Charity National Health System, St. Louis; Mount Sinai Medical Center, Miami Beach, Fla.; SSM Health Care in St. Louis; and Montefiore Medical Center, Bronx, New York. In addition to his current roles at Ascension Health and Ascension, he currently serves as Board Chair of the Catholic Health Association; Board member with the United Way of Greater St. Louis; Board member with the Coalition to Protect America’s Health Care; Fellow of the American College of Healthcare Executives; and member of the Healthcare Executives Network. He is a University of Pittsburgh Legacy Laureate. Mr Henkel received a Bachelor’s degree in Economics from Union College, Schenectady, New York, and a Master’s degree in Public Health from the University of Pittsburgh, where he now serves as an Adjunct Professor in the Graduate School of Public Health.

Michelle Larkin

Michelle Larkin

Associate Chief of Staff and Associate Vice President-Program
Robert Wood Johnson Foundation

Michelle Larkin, Associate Chief of Staff and Associate Vice President – Program, directs program and administrative activities at Robert Wood Johnson Foundation. She helps shape the Foundation’s strategies, policies and impact; building a culture of health for our nation where everyone has the opportunity to live healthier lives, no matter where they live or how much they make.

Before joining the Foundation, Ms Larkin worked as an oncology nurse at the University of Maryland Medical System in Baltimore, where she experienced the opportunities, challenges and rewards of bedside nursing. She left bedside nursing to focus on population health improvement through systems, law and policy change at the federal level. She has worked at the Office on Smoking and Health, Centers for Disease Control and Prevention (CDC) and the US Senate Labor and Human Resources Committee, as well as the Office on Smoking and Health, CDC, in Washington, D.C.

Ms Larkin received a JD from Seton Hall University School of Law, an MS in nursing/health policy from the University of Maryland and a BSN from the University of Pennsylvania.

Daniel Barchi

Daniel Barchi

Senior Vice President and Chief Information Officer
New York Presbyterian

Daniel Barchi is Senior Vice President and Chief Information Officer of New York-Presbyterian, one of the largest healthcare providers in the US and the University Hospital of Columbia and Weill Cornell. He leads a team of more than 700 informatics and technology specialists who deliver the tools and data that physicians and nurses use to deliver acute care and manage population health.  Before joining New York-Presbyterian, Mr Barchi was Chief Information Officer of the Yale School of Medicine and Yale-New Haven Health System. In that role he established nation-leading analytics and clinical research technology practices and led a $300m Electronic Medical Record project. Before joining Yale, he was Senior Vice President and CIO of the $1.4bn Carilion Health System, and led the integration of Carilion’s operations through implementation of Electronic Medical Records at seven hospitals and 140 physician practices.Mr Barchi was previously President of the Carilion Biomedical Institute and Director of Technology and Engineering for MCI WorldCom. In both roles, he was appointed as CEO, COO, and Chief Restructuring Officer of privately held and venture-backed companies in the healthcare and technology industries. Earlier, Mr Barchi served as MCI's Director of Global Project Management responsible for product deployment in Europe, Asia, and the Americas. Mr Barchi began his career as a US Naval officer at sea on guided-missile cruisers. During his service, he was awarded the Navy Commendation Medal, the Southeast Asia Service Medal for Iraq operations in the Red Sea, and the NATO Service Medal for Bosnia operations in the Adriatic Sea.

Mr Barchi holds a BS from Annapolis, the US Naval Academy, and a Master of Engineering Management from Old Dominion University. He is faculty at Yale University.

Josh  Bruno

Josh Bruno

Founder and CEO

Josh Bruno is Founder and CEO of Hometeam, Mr Bruno founded Hometeam when his family struggled to care for his 93-year-old grandfather. He believes that home care should go beyond the basics to provide a safe, reliable, and interactive service that creates happier days for seniors. Prior to Hometeam, Mr Bruno worked as an investor, operator, and engineer at companies to include Bain Ventures, Bain & Co, and Yahoo.

Steve Cutler

Steve Cutler


Steve Cutler was appointed Chief Executive Officer of ICON plc in March, 2017, and serves on ICON’s Board of Directors. ICON is a global leader in the provision of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Renowned for delivering excellence and innovation in the drug development process, ICON counts all of the world’s leading pharmaceutical and biotechnology companies amongst its customers. The company has particular expertise in helping transform pharma R&D through strategic partnerships and alliances. Dr Cutler joined ICON in 2011 as Group President, Clinical Research Services and was appointed Chief Operating Officer in January 2014, where he led ICON’s global operations, strategic customer alliances and the management of more than 460 clinical development projects from Phase IIb - IV. Dr Cutler has over 25 years of experience in the pharmaceutical and CRO industries. Prior to joining ICON, he was Chief Executive Officer of Kendle and oversaw the sale of the company to INC Research. Prior to Kendle, he held various operational and general management roles in both Quintiles and Sandoz (Novartis). Dr Cutler holds a BSc and a PhD from the University of Sydney and a Masters of Business Administration from the University of Birmingham.

Jeffrey Dachis

Jeffrey Dachis

Founder and CEO
One Drop

Jeff​ Dachis is the Founder and CEO of One Drop, a simple, powerful and convenient mobile platform for managing diabetes, born from his own experience as a Type 1 person with diabetes. His desire to bring the quantified self movement, internet of things, big data and mobile computing to people with diabetes in a simple, fully integrated solution led him to create the award winning One Drop platform. Prior to One Drop, Mr Dachis was ​the Founder, CEO and Chairman of Dachis Group and drove the eventual strategic sale to Sprinklr, the leading social experience management platform. Mr Dachs is also the Co-Founder, former CEO and Chairman of Razorfi​sh, the world’s largest digital marketing solutions firm​ where he bootstrapped the company and led it through its successful $55m IPO and eventual $6bn market capitalization. ​

Joe Damore

Joe Damore

Vice President, Population Health Management

Joe Damore is Vice President, Population Health Management, Premier. In this role, he is responsible for a team of health care consultants who assist hospitals, physicians and health systems in developing integrated health systems and in implementing accountable care organizations. He provides consultative assistance to Population Health Collaborative members and advises numerous healthcare organizations in areas such as strategic business planning, clinical integration and quality and financial improvement.

Prior to joining Premier, Mr Damore served as CEO of Mission Health System from 2004 to early 2010 and the Sparrow Health System from 1990 to 2004. Prior to his tenure as a CEO, he served as an executive with Mercy Health Services (Trinity Health), Western Reserve Care System and Greenville (S.C.) Health System. He also was President of JFD Consulting, LLC, an advisory firm focused on helping hospitals and health systems prepare for health care reform and in the development of integrated health systems and accountable care organizations. His entire 35 year career as a healthcare leader has focused on building and developing regional integrated health systems, including integrating comprehensive delivery systems and health plans. In addition, he helped found and served as Executive Director of a new national coalition of hospital and health system (not for profit) sponsored health plans (HHP). Mr Damore holds a BA degree from Thiel College in Greenville, PA, and a Master’s degree in Health Administration from The Ohio State University. He is a Fellow of the American College of Healthcare Executives and most recently served as Board Chair of The Ohio State University Alumni Association, on the Board of Directors of the University of North Carolina-Asheville and on the board of the Alliance for the Advancement of nonprofit Health Care.

Senator Tom  Daschle

Senator Tom Daschle

Founder and CEO
The Daschle Group

Senator Daschle is the Founder and CEO of The Daschle Group, a public policy advisory of Baker Donelson. Senator Daschle served his home state, South Dakota, in the US House of Representatives from 1979 until 1987 and in the US Senate from 1987 to 2005. He is one of only two senators to have served twice as both majority and minority leader. In addition, Senator Daschle is Chair of the Board of Directors at the Center for American Progress, Vice-Chair for the National Democratic Institute and a Co-Founder of the Bipartisan Policy Center. He is the author of Like No Other Time: The 107th Congress and the Two Years That Changed America Forever;Critical: What We Can Do About the Health-Care Crisis; Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform, and U.S. Senate: Fundamentals of American Government. He co- authored his most recent book, Crisis Point, with former Senator Trent Lott.

Alyse Forcellina

Alyse Forcellina

Leader, US Healthcare Practice
Egon Zehnder

Alyse Forcellina leads the US Health Practice and advises Egon Zehnder clients on broad-ranging talent matters, including organizational design, leadership assessment and development, and succession planning. Her industry area of passion and focus is healthcare, where she works with biopharma and healthcare services companies to find top executive talent and Board members. Leveraging her background in strategy and finance, Ms Forcellina helps organizations harness talent to meet their strategic and operational goals within the ever-changing global marketplace. She is certified in the 16pf and the Hogan Development survey, and is trained in a variety of leadership and coaching frameworks. Prior to joining Egon Zehnder, Ms Forcellina was an Associate Principal at McKinsey & Company, where she helped healthcare clients solve both commercial and organizational challenges, with a particular emphasis on capability building. As a Senior Principal at IMS Consulting, she was a leader in the North American practice, where she helped double revenues and developed a best-in-class leadership team. Previously, she was Managing Director of True North Partners, a boutique healthcare consultancy, where she built the consulting practice. Earlier in her career, Ms Forcellina was an Associate with a boutique investment bank, advising biotech, diagnostics and medical device companies on M&A transactions and capital structure. She started her career on Capitol Hill working for a United States Senator, writing healthcare legislation. Ms Forcellina earned a BA in American Studies at Yale, an MPAff from Lyndon B. Johnson School of Public Affairs and an MBA from McCombs School of Business, both at the University of Texas.

Damon Francis

Damon Francis

Chief Medical Officer
Health Leads

Damon Francis is Chief Medical Officer at Health Leads. He joined Health Leads after five years in the Alameda County Health Care Services Agency in the East San Francisco Bay Area, where he worked on all aspects of the Agency’s vision for “healthy people, places, policies and systems.” As Interim Director and Medical Director of Health Care for the Homeless, Dr Francis led the adoption and expansion of clinical models addressing the whole person including medical, behavioural, and social needs. Much of his work leveraged new funding opportunities under the Affordable Care Act. His roles in the program ranged from clinician to manager to payer, allowing him to experience both the bewildering complexity of health care payment models, and the awesome diversity of human resilience. Previously, Dr Francis served as the Medical Director of the Urban Male Health Initiative, where he worked to reduce health disparities affecting men of color, providing policy analysis and representing the public health department in cross-governmental initiatives and public-private partnerships related to housing, criminal justice, and clinical quality improvement. He also worked at the East Bay AIDS Center in Oakland, California, where he helped drive innovations such as marketing through social networks, providing strong peer supports, and involving patients in clinic design, each of which has led to improvements in care for a group that has historically been served very poorly by the healthcare system. Dr Francis is an Assistant Clinical Professor at the University of California, San Francisco, where he completed medical school and residency in primary care internal medicine and served as Chief Resident for the Internal Medicine Service at San Francisco General Hospital. His clinical experience since residency includes inpatient and outpatient practice in public, private, and academic settings, and he continues to provide urgent care at a community clinic in Oakland.

Dedi Gilad

Dedi Gilad

CEO and Co-Founder
Tyto Care

Dedi Gilad is CEO and Co-Founder, Tyto Care. With over 18 years of experience in leadership positions both in startups as well as global companies, Mr Gilad brings extensive knowledge and hands-on experience in R&D, marketing and operations of multi-disciplinary products in the fields of healthcare IT, enterprise systems, internet and SaaS. Before founding Tyto Care, Mr Gilad was General Manager at MDG Medical, Vice President of R&D at WorkplaceIQ (acquired by Siterra / Accruent) and Vice President of R&D at Aman Group. Mr Gilad earned an MBA and a BSc in Industrial Engineering from the Tel-Aviv University.

Douglas Henley

Douglas Henley

Executive Vice President and Chief Executive Officer
American Academy of Family Physicians

Douglas Henley serves as Executive Vice President and Chief Executive Officer for the American Academy of Family Physicians (AAFP). The AAFP is the medical specialty organization representing 124,900 family physicians and medical students nationwide. Mr Henley has served on the board of directors of the Patient-Centered Primary Care Collaborative since its founding and is the Immediate Past Chair. He served as a commissioner on the American Health Information Community, and was one of the inaugural commissioners of the Certification Commission for Healthcare Information Technology. He is a past President of the AAFP (1995-1996). Mr Henley is a graduate of the University of North Carolina School of Medicine, Chapel Hill, and its’ family medicine residency program, is board certified by the American Board of Family Medicine and has the AAFP Degree of Fellow, a degree awarded to family physicians for distinguished service and continuing medical education.

Peter Keeling

Peter Keeling

Chief Executive Officer

Peter Keeling is Chief Executive Officer of Diaceutics, a global group of experts from the laboratory, diagnostic and pharmaceutical industries. Mr Keeling recognized early on that precision medicine would be an increasingly large part of the drug development paradigm, representing a shift in how the pharmaceutical industry operates. His role with Diaceutics complements over thirty years’ experience in international healthcare which began at GSK and Diagnology. He has operated and led companies and teams in the US, Europe, Asia and BRIC countries, inspiring product innovation and global launches while repeatedly delivering high corporate value growth for shareholders. Mr Keeling has spent two extended periods in applied industrial research, including a year at MIT’s Pharmaceutical Program at the Sloan School of Management in Boston. He has also been published widely in peer reviewed economic and precision medicine journals, is a seasoned speaker and is considered one of the world’s thought leaders in diagnostic launch commercialization in support of optimizing therapy.

Aaron  Kesselheim

Aaron Kesselheim

Associate Professor of Medicine
Harvard Medical School

Aaron. Kesselheim, MD JD MP, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital (BWH). His work addresses a number of topics at the intersection of law, medicine, and ethics, including FDA regulatory policies and the approval process for prescription drugs and medical devices and the costs, availability and evidence-based use of prescription drugs. He graduated from Harvard College and received his postgraduate training at the University of Pennsylvania School of Medicine and Law School and most recently at the Harvard School of Public Health. He is Board Certified in Internal Medicine, and serves as a primary care physician at the Phyllis Jen Center for Primary Care at BWH. Within the Division, Professor Kesselheim created and leads the Program On Regulation, Therapeutics and Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes and regulatory practices and the law. Professor Kesselheim is a member of the New York State Bar and is a Patent Attorney.

David Lansky

David Lansky

President and Chief Executive Officer
Pacific Business Group on Health

David Lansky is the President and Chief Executive Officer of the Pacific Business Group on Health (PBGH) – directing efforts to improve the affordability and availability of high-quality health care. Since 2008, he has led the coalition of 60 large employers and health care purchasers representing more than 6 million Americans, including Wells Fargo, Intel, Safeway, Walmart, Boeing, CalPERS, and the state of Washington Health Care Authority. Mr Lansky is also currently the Vice Chair of the Health Care Transformation Task Force. He also serves on the Guiding Committee of the HHS Learning and Action Network, the Congressional Budget Office Health Advisors Panel and the Board of the Alliance for Health Reform. A nationally-recognized expert in accountability, quality measurement and health IT, Mr Lansky has served as a board member or advisor to numerous health care programs, including the National Quality Forum, Federal Health IT Policy Committee, Catalyst for Payment Reform, Joint Commission, National Patient Safety Foundation, Leapfrog Group, and the Medicare Beneficiary Education Advisory Panel. From 2004 to 2008, Mr Lansky was Senior Director of the Health Program at the Markle Foundation (NY), and from 1995 to 2004, he established the Foundation for Accountability (FACCT), a public-private venture developing quality measures and web-based tools to help consumers and purchasers assess the value of health care services and providers. Mr Lansky was a Senior Policy Analyst for the Jackson Hole Group during the national health care reform debate of 1993-94. He led the Center for Outcomes Research and Education at Oregon-based Providence Health System from 1988 to 1993. He is the author of more than 30 peer-reviewed papers on outcomes research and quality measurement and holds a PhD from the University of California, Berkeley.

Jeff  Marrazzo

Jeff Marrazzo

Spark Therapeutics

Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children's Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. He also serves on Spark Therapeutic’s board of directors. Under Mr Marrazzo’s leadership, the company has successfully completed the first randomized, controlled Phase 3 trial of an investigative gene therapy for a genetic disease and established human proof-of-concept of a gene therapy platform in both the retina and the liver. The company is currently preparing the first Biologics License Application submission for a gene therapy for a genetic disease in the US. During a career that has spanned the public and private sectors, Mr Marrazzo has consistently championed the potential benefits of precision medicine and healthcare reform for patients. Prior to Spark Therapeutics,, he helped build and sell the first genetic testing benefit management and pharmacogenomics medicines company to CVS Caremark. Previously, Mr Marrazzo served as an advisor to former Pennsylvania Governor Edward G. Rendell, where he led reforms in the financing and delivery of healthcare. Mr Marrazzo received a BA. in Economics and BSE in Systems Science and Engineering from the University of Pennsylvania. He also holds a dual MBA / MPA from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded.

Justin McCarthy

Justin McCarthy

Senior Vice President, Patient and Health Impact Group

Justin McCarthy is Senior Vice President, Patient & Health Impact group, part of the Chief Business Office at Pfizer. The Patient & Health Impact group brings together experts in health economics and outcomes research, real-world data and analytics, patient-centered outcomes assessment, market access, pricing, strategy and contracting, who generate evidence of the value of Pfizer medicines and vaccines and negotiate with governments and payers in the US and around the world to ensure access for patients. This group is also leading Pfizer’s work to explore novel approaches to commercialise medicines through innovative partnerships and payment models.

Prior to this role, Mr McCarthy was Senior Vice President, Global Policy & International Public Affairs, responsible for defining Pfizer’s public policy positions on US healthcare at the federal and state level and advancing government and public affairs strategies internationally. Mr McCarthy has been with Pfizer for 25 years and was formerly Chief Counsel for Pfizer’s Worldwide Research and Development division, advising on regulatory, licensing and clinical trial issues, and overseeing global intellectual property activities. He has extensive experience negotiating Pfizer’s research collaborations and partnerships with government, academic institutions and biotechnology companies.

Mr McCarthy serves on the boards of the National Pharmaceutical Council, Vivli Inc. and sits on the Portfolio and Strategic Investment Committee (PSI) within Pfizer which is the company’s governance body that oversees the R&D investments and strategy.

Prior to joining Pfizer, Mr McCarthy was an associate in the law firm of Keller & Heckman. Mr McCarthy holds a Bachelor’s degree in Pharmacy from the University of Rhode Island and law degree from the Catholic University of America.

Robert McMahon

Robert McMahon

President, US Market, Global Human Health

Robert McMahon is the President of Merck’s US Market, a region of the Global Human Health division. In this role, Mr McMahon leads a team of 4,000 employees responsible for all sales, marketing and business operations supporting the commercialization of pharmaceutical products promoted by Merck in the United States. The US is Merck’s largest market, with sales of more than $20bn in 2014. From 2012 until 2013, Mr McMahon served as Senior Vice President of Government Relations, Public Policy and Corporate Responsibility, where he was instrumental in shaping Merck’s response to the changing US healthcare environment, including the introduction of the Affordable Care Act (ACA). Over the course of his 33-year career, Mr McMahon has developed a reputation as a passionate, results-oriented leader. A CPA by training,Mr McMahon began his Merck career in finance and has since held a variety of commercial roles with both domestic and international responsibilities. With more than 25 years of experience in the US Market, Mr McMahon has led important launches for HIV, cardiovascular disease and diabetes. He also has been an architect and sponsor of organizational change and the evolution of the Merck commercial model over the last ten years. Mr McMahon serves as a member of the Board of Trustees for the Children’s Inn at the National Institutes for Health, and the Dean’s Advisory Council for the Villanova School of Business. Before joining Merck, Mr McMahon worked for the Squibb Corporation and Arthur Andersen & Co. Mr McMahon is a graduate of Villanova University where he earned a Bachelor of Science degree in Accounting.

Mark   Merritt

Mark Merritt

President and Chief Executive Officer
Pharmaceutical Care Management Association

Mark Merritt is President and CEO of the Pharmaceutical Care Management Association (PCMA), the national association representing America’s pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 266 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.

Mr Merritt took the helm of PCMA in March 2003 and quickly raised the industry’s profile. He is repeatedly ranked as one of the most effective trade association CEOs in America and has been inducted into the U.S. Chamber of Commerce’s elite “Association Committee of 100,” representing America’s top trade association executives. In recognition of his aggressive advocacy for lower cost prescription medications, the Generic Pharmaceutical Association (GPhA), which represents the world’s leading generic drug manufacturers, honored Mr Merritt with its prestigious “Outstanding Contribution” award. Mr Merritt serves on the Editorial Advisory Board for Drug Benefit News and on the Board of Directors for the Public Affairs Council, the leading association for public affairs professionals worldwide.

Mr Merritt is credited with designing and implementing innovative, campaign-style strategies that go beyond traditional Washington-style lobbying campaigns. Mr Merritt has pioneered strategies that reach beyond the boundaries of Washington politics to communicate more effectively with diverse constituencies from Wall Street to Main Street to Hollywood.

Prior to PCMA, Mr Merritt served as a senior strategist with America’s Health Insurance Plans and the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as with the presidential campaigns of current US Senator Lamar Alexander and former Senator Robert Dole.  Mr Merritt has also served as a Fellow at Harvard University’s John F. Kennedy School of Government, where he lectured on the intersection between public policy and the news media.

He holds both an MA and BA from Georgetown University.

Jason  Park

Jason Park

Flagship Pioneering

Jason Park is a Principal at Flagship Pioneering and focuses on life science investments. He is based in New York City, where he is helping lead the firm’s activities in the development of the city’s life sciences industry.
Prior to joining Flagship, Mr Park was with the Boston Consulting Group (BCG)  where he was a core member of the Health Care, Strategy, and Technology teams. He led projects across a broad variety of topics, including early stage R&D, portfolio investment strategy, biopharmaceutical manufacturing, strategic and commercial due diligence, and global health. His time at BCG included wide geographic exposure, including years abroad as a member of the Mumbai and Paris offices. Earlier in his career, Mr Park was a Director at an early stage biotech start-up focused on targeted drug delivery as well as the co-founder of an internet advertising firm.

Mr Park holds a PhD., an M.S. and a B.S. in biomedical engineering from Yale University where he continues to serve as an external venture creation mentor. His research focused on the use of nanotechnology for immunomodulatory purposes and he is the author of several book chapters and numerous peer-reviewed publications.

Dr Jose  Peña

Dr Jose Peña

Chief Executive Officer and Chief Medical Director
Rio Grande Valley Accountable Care Organization (RGV ACO)

Jose Peña, MD, FACP, FACHE, is Chief Executive Officer and Chief Medical Director of Rio Grande Valley Accountable Care Organization Health Providers, LLC (RGV ACO). He has served in these roles since its inception in 2012. His primary focus areas include process improvement, population health, and innovations in patient-centered diabetes management. Currently practicing, he leads a value-based oriented medical group recognized as a Level 3 Patient Centered Medical Home. RGV ACO has become one of the most successful ACOs as measured by both quality metrics and cost savings. Prior to working with RGV ACO, Dr Peña served in a variety of leadership roles including Chief of Staff and Board Member at Doctor’s Hospital at Renaissance. Dr Peña is board certified in internal medicine, palliative medicine, and medical management. Dr Peña completed post-graduate training in internal medicine at St. Barnabas Hospital in New York City, where he was named “Resident of the Year”.

Adam Pellegrini

Adam Pellegrini

Vice President of Digital Health

As Vice President of Digital Health at Fitbit, Mr Pellegrini is responsible for leading the vision, strategies and programs that support Fitbit’s integration into healthcare systems around the world. In his role, he harnesses the power of Fitbit products, software and services to help create better clinical health outcomes, while identifying new revenue opportunities that will build on the company’s current momentum in disease management, insurance and wellness programs. Previously, he served as Vice President of Digital Health at Walgreens Boots Alliance, where he led a team of seasoned industry executives to build out the next generation of digital and mHealth platforms. He also led marketing and product strategy at HealthyCircles, worked as a product manager for Microsoft Healthvault and managed the online strategy for the American Cancer Society.

Anne Phelps

Anne Phelps

Principal, US Healthcare Regulatory Leader

Anne Phelps is a Deloitte Advisory Principal in the Life Sciences and Health Care practice of Deloitte & Touche LLP. She has over twenty-seven years of health care policy experience in a broad range of legislative and regulatory issues. Ms Phelps serves as a strategic business advisor to numerous health care stakeholders - including providers, payers, employers, life sciences companies, and investors - to help them navigate the complex health care regulatory environment and how it will impact their organizations. This involves understanding the regulatory landscape, interpreting the impact on the various stakeholders, and helping organizations scenario plan, formulate priorities, and execute their strategies.

Prior to her career in professional services, Ms Phelps served in the Bush Administration as a Special Assistant to the President as the Chief Health Policy Advisor to the President for the Domestic Policy Council and as the Executive Director of the 2004 Republican National Platform Committee. Earlier in her career, Ms Phelps worked on Capitol Hill in the United States Senate and at the National Institutes of Health in a variety of health policy and legislative roles.

Michael  Rea

Michael Rea

Founder and CEO
Rx Savings Solutions

Michael Rea founded Rx Savings Solutions in 2008 after routinely witnessing consumers struggling to pay for their medications. He noticed quickly at that time that consumers were paying much more than they needed to, which was attributable to a lack of information available to them. He set out on his mission to arm consumers with this information and add efficiency and transparency back into the world of pharmacy. Dr Rea has been involved with research surrounding pharmacy transparency for over 10 years. He received his Doctor of Pharmacy degree from Creighton University.

Jeffrey  Riley

Jeffrey Riley

Chief Executive Officer, President and Director
Synthetic Biologics

Jeffrey Riley is the CEO, President and Director of Synthetic Biologics. With more than 20 years of experience in the biotechnology and pharmaceutical industries, he has negotiated numerous worldwide strategic corporate alliances, established joint ventures, and assisted in obtaining venture financings to support product development. Most recently, he served as Managing Director of 526 Ventures. Prior to this, he was a venture partner with QIC Bioventures Fund, held senior positions within the mergers & acquisitions and in-country management groups at SmithKline Beecham and Pfizer, and served as Chief Financial Officer and Vice President, Corporate Development for Nichols Institute Diagnostics, later acquired by Corning and spun out to Quest Diagnostics, Inc. Mr Riley holds a Bachelor of Science degree from Boise State University, completed coursework at UCSF/Berkeley in Drug Discovery/Development and completed a dual-degree graduate program (MBA/MIM) sponsored by Arizona State University and the Thunderbird School of Global Management.

Mario  Schlosser

Mario Schlosser

CEO & Co-Founder

Mario Schlosser is the CEO and Co-Founder of Oscar, a health-insurance start-up that is using technology, design, and data to help humanize and simplify healthcare. Previously, he co-founded the largest social gaming company in Latin America, where he led the company's analytics and game design practices. In an earlier position at Bridgewater Associates, Mr Schlosser developed analytical trading models as a Senior Investment Associate. Prior to Bridgewater, he worked as a consultant for McKinsey & Company in Europe, the US and Brazil. As a visiting scholar at Stanford University, Mr Schlosser wrote and co-authored 10 computer science publications, including one of the most-cited computer science papers published in the past decade, in which he developed an algorithm to securely compute trust in randomized networks. Mr Schlosser holds a degree in Computer Science with highest distinction from the University of Hannover in Germany and an MBA from Harvard Business School.

Roy	 Schoenberg

Roy Schoenberg

President and CEO
American Well

Roy Schoenberg founded American Well in 2006 and currently oversees operations as the company’s President and Chief Executive Officer. He also serves on the Board of the American Telemedicine Association. Dr Schoenberg was instrumental in the development of the company’s core technology, a brokerage engine that connects patients and providers for telemedicine visits. Prior to American Well, Dr Schoenberg founded CareKey, a supplier of chronic condition management software. Following the acquisition of CareKey by TriZetto, Dr Schoenberg served as that company’s Chief Information Security Officer. He is an avid author and speaker in the areas of healthcare technology and Health IT policy. In 2013, he was appointed to the Federation of Medical Board’s task force delivering landmark guidelines for the ‘Appropriate use of Telehealth in Medical Practice’.In 2014, he received the American Telemedicine Association Industry award for Leadership in the field of Telemedicine. Dr Schoenberg holds an MD from the Hebrew University and an MPH from Harvard University.

Julie  Staudenmier

Julie Staudenmier

Senior Director Global Learning and Development

Julie Staudenmier is Senior Director, Global Learning and Development at Pfizer. In this role, she has responsibility for developing and executing Pfizer's global learning and leadership development strategy.  Global Learning &Development directly connects to Pfizer's strategic imperatives and contributes to the growth and development of leadership at every level, including individuals, managers, and senior leaders. Prior to joining Pfizer, Ms Staudenmier held executive level human resource positions at Boehringer Ingelheim, American Express, Sony and TD Ameritrade. In these positions, she led initiatives in executive and leadership development, succession planning and talent management, corporate learning and development, talent acquisition, resource planning and organizational development. Earlier in her career, Ms Staudenmier  was a partner with Executive Development Associates (EDA), a boutique consulting firm focusing on strategic executive development. Ms Staudenmier has a Masters in Industrial/Organizational Psychology from Wayne State University and a BA in Psychology and Sociology from South Dakota State University.

Ramita  Tandon

Ramita Tandon

Executive Vice President, Commercialisation and Outcomes

Ramita Tandon is Executive Vice President, Commercialization & Outcomes Services, ICON, a position she has held since December 2015. In her current role, she leads the company’s Commercialization and Outcomes service area, which helps clients to optimize the value of drugs and medical devices through strategies and tactics that reflect evolving evidentiary, regulatory, and reimbursement requirements. She has been involved in the drug development industry for over 20 years with a focus on building new opportunities for various clinical research organizations. Ms Tandon is a recognized thought leader and provides regular industry commentary on areas including the late phase market, product commercialization, and bridging the silos between clinical and commercial groups to optimize product value. Ms Tandon’s passion and commitment in the commercial and outcomes domain stems from her belief that the commercial model is ripe for significant change and innovation and will continue to serve as a driving force in the overall healthcare ecosystem.

Stephen Ubl

Stephen Ubl

President and CEO
Pharmaceutical Research and Manufacturers of America (PhRMA)

Stephen J. Ubl is President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. Mr Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. He is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. As president and CEO of medical technology association AdvaMed, Mr Ubl helped facilitate landmark reforms related to the US Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry. Mr Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation). He is routinely recognized as one of Washington’s most effective advocates, and, in 2018, was named for the third year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare” and a top health influencer by Medical Marketing & Media and PR Week magazines. Prior to AdvaMed, Ubl was vice president of legislation for the Federation of American Hospitals. He began his Washington career on Capitol Hill.

Janet Vergis

Janet Vergis

Former CEO, OraPharma
Executive Advisor to private equity

Janet Vergis has over 29 years of experience in the healthcare industry and currently serves as an Executive Advisor to private equity. She was most recently Chief Executive Officer of OraPharma, where she led the successful turnaround of the company and its subsequent sale. Prior to these roles, Ms Vergis managed a $6 billion portfolio at Johnson & Johnson as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologics. Ms Vergis currently serves on the Board of Directors for Church and Dwight Co., Inc., Impax Laboratories, Inc., and MedDay Pharmaceuticals, and is Chairman of The Biotech Advisory Board and a Member of the Dean’s Advisory Counsel for The Eberly College of Science at The Pennsylvania State University. Ms Vergis earned a BS degree in Biology and an MS degree in Physiology from Penn State.

Frank   Westermann

Frank Westermann

CEOrand Co-Founder

Frank Westermann is CEO and Co-Founder of mySugr, a digital health start-up founded in 2011 with offices in Vienna, Austria and San Diego, California. mySugr helps around one million patients worldwide to manage their diabetes through its mobile services. Prior to his current position, Mr Westermann worked in various leading Business Development positions in the telecommunications industry in Germany and Austria for companies to include Telekom Austria or iTV solutions. He has a Master’s degree in Business Development from the University of Applied Sciences in Dusseldorf.


Chair and Moderators (3)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Sarah  Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Sarah Thomas

Sarah Thomas

Managing Director, Deloitte Center for Health Solutions

Sarah Thomas is the Managing Director of the Deloitte Center for Health Solutions, part of Deloitte LLP’s Life Sciences and Health Care practice. As the leader of the Center, she drives the research agenda to inform stakeholders across the healthcare landscape about key trends and issues facing the industry. Ms Thomas was previously Vice President for Public Policy and Communications at the National Committee for Quality Assurance (NCQA), where she was responsible for the development of NCQA’s public policy strategy, its work with the federal and state government, as well as its media and communications operations. She also served as the Director of the Public Policy Institute (PPI) Health Team at AARP. She oversaw AARP’s advocacy in areas of cost, access, and quality related to health care reform, Medicare, Medicaid, prescription drugs, private insurance, and public health.

In addition to her nonprofit work, Ms Thomas has 14 years of experience in the federal government. She was Deputy Director at the Medicare Payment Advisory Commission (MedPAC) and served at the Congressional Budget Office and the Centers for Medicare and Medicaid Services (CMS). Ms Thomas has worked for national associations, in state government, and for the Advisory Board Company. She holds a MS in Health Policy and Management from the Harvard School of Public Health.

Agenda - 18th May

  • 8:00am
    Registration and Breakfast
  • 8:30am
    Breakfast Briefing: Leveraging diagnostics and analytics (Dx) to boost therapy return on investment - a 360° review

    With over $200bn of drug revenue already shaped by diagnostics and 70% of future pipelines biomarker enabled, the dependence of the future pharma business model on integrating diagnostics is no longer in question. However, this throws into sharp focus the readiness of the industry to understand and optimize the clinical diagnostic ecosystem underpinning every therapy launch. The question is no longer “which patients tested positive for a targeted therapy choice?” but rather “how many of the right patients were not tested and missed the treatment opportunity?”

    This briefing will quantify the missed treatment opportunity based on real time/real world US testing data, and discuss the readiness of the pharma industry to radically improve patient testing in support of improving outcomes and accessing higher return on personalized medicine investments.

    Peter Keeling, Chief Executive Officer, Diaceutics

  • 9:00am
    Opening Remarks from the Chair

    David Crow, Senior US Business Correspondent, Financial Times

  • 9:05am
    Opening Keynote Address

    Dieter Weinand, Member of the Board of Management and President Pharmaceuticals, Bayer 

  • 9:30am
    Panel: US Healthcare Reform: Risk and Opportunity in the New Health Economy

    With the recent passage of the American Healthcare Act through the House of Representatives, and the potential unraveling of the Obamacare reforms that have dominated the industry agenda in recent years, the stage seems set for a period of continued disruption and uncertainty. How will the future unfold? What are the risks and opportunities as we move forward with reforms? How will the competitive landscape of the industry evolve?

    David Blumenthal, President and CEO, The Commonwealth Fund
    Senator Tom Daschle, Founder and CEO, The Daschle Group
    Mario Schlosser, CEO & Co-Founder, Oscar
    Robert McMahon, President, US Market, Global Human Health, Merck

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 10:30am
    What is the Price of a Drug?

    The furor over drug prices in the US looks set to continue under the new Republican-led Administration, with little evidence of workable and politically acceptable solutions in sight. As prices rise, drugmakers are playing down their role, and are instead blaming the middlemen - the wholesalers, pharmacies and pharmacy benefit managers (PBMs)  - who take their own cut of the price. The rebate system, whereby PBMs take a percentage share of the rebates they win for purchasers, it is claimed, encourages price inflation. Value judgements,meanwhile, according to the pharma industry, are too often based on the wholesale price of the drug.  Is the current rebate system dysfunctional and in need of reform, or are the middlemen a convenient scapegoat for a pharma industry under pressure? In considering the alternative solutions, what are the prospects for legislative changes to control prices? What are the solutions for the current impasse?

    Justin McCarthy, Senior Vice President, Global Policy and International Public Affairs, Pfizer 
    Steve Miller, Senior Vice President and Chief Medical Officer, Express Scripts 
    Aaron Kesselheim, Associate Professor of Medicine, Harvard Medical School
    Michael Rea, Founder and CEO, Rx Savings

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 11:10am
    Networking Coffee Break
  • 11:25am
    Panel: MACRA and Beyond: How Value is Transforming the Business Model of the Industry

    With strong bipartisan support, payment reform looks set to remain a mainstay of efforts to achieve more affordable and accountable care. While we are still in the first innings in the move from fee-for-service to value- based care, the transition has already been game-changing across the industry-for payers, providers, life science companies, for patients and for the competitive landscape of the industry. Payments based on outcomes are expected to dwarf fee-for-service payments by 2020, and The Medicare Access & CHIP Re-authorization Act 2015 (MACRA) - the new system for medicare funded physicians based on outcomes - is expected to considerably accelerate the transformations already underway. What are the impacts and implications of MACRA? What have been the successes, challenges (for instance in the allocation of risks), margin impacts and learnings from the transition to date-the direct and indirect consequences of the payment reforms? What is the key to surviving and thriving in the new payment landscape?

    Douglas Henley, Executive Vice President and Chief Executive Officer, American Academy of Family Physicians
    David Lansky, Chief Executive Officer, Pacific Business Group on Health
    Anne Phelps, Principal, US Healthcare Regulatory Leader, Deloitte
    Ramita Tandon, Executive Vice President, Commercialization and Outcomes Services, ICON

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 12:15pm
    FT CEO Keynote Interview

    Steve Cutler, Chief Executive Officer, ICON

  • 12:35pm

    FT Keynote Interview:

    Stephen Ubl, President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America (PhRMA) in  conversation with David Crow.

  • 1:40pm
    Is the Future of Healthcare Virtual? Prospects for Home Care and Telehealth

    An ageing population, soaring healthcare costs, the rapid development in enabling technologies as well as supportive regulation and new payment models are driving interest and increased investment in telehealth and home care services. With the number of those aged 65 or older expected to increase at 5 times the rate of the rest of the population by 2040, for instance the opportunity for savings in treating patients outside of the traditional hospital setting is significant. What is the business case/the ROI in investment in telehealth and home care? Will it ultimately increase, or decrease costs for the system? Will it lead to greater fragmentation of healthcare? What are the consumer expectations and preferences regarding care in the home? What are the implications for traditional healthcare providers- how can they reposition their business to accommodate for the changing delivery system?

    Daniel Barchi, Senior Vice President and Chief Information Officer, New York Presbyterian Hospital
    Josh Bruno, Founder and CEO, Hometeam
    Dedi Gilad, CEO and Co-Founder, Tyto Care
    Roy Schoenberg, President and CEO, American Well

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 2:20pm
    Tackling the Social Determinants of Health: The Next Big Challenge

    With the growing recognition that up to 40% of an individual’s health is determined by circumstances outside of the clinic, the government is encouraging healthcare companies to become more involved in influencing broader social determinants of health to include lack of housing, poverty and crime. A small but growing number of healthcare organizations are investing in such community benefit programs in line with evolving payment models supporting such activities. What are the societal determinants of health and which, if any, can health companies control? Are health companies, in reality, the best equipped to address social ills? How is the reimbursement regime payments regime evolving to support community benefit programs? How can outcomes be measured and attributed? What are the experiences of healthcare providers who have successfully embarked on such initiatives? Will we see these efforts spread more widely across the industry? 

    Tanisha Carino, Vice President, US Public Policy, GlaxoSmithKline
    Damon Francis, Chief Medical Officer, Health Leads
    Robert Henkel, President and Chief Executive Officer, Ascension Health; Executive Vice President, Ascension
    Michelle Larkin, Associate Chief of Staff and Associate Vice President -Program, Robert Wood Johnson Foundation

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 3:00pm
    Networking Coffee Break
  • 3:15pm
    Managing the Cost of Diabetes Care: Front Line Perspectives

    Many in the healthcare system recognize that some of the greatest opportunities for lowering costs of care and enhancing outcomes are centred around managing chronic diseases, and diabetes in particular as one of the more prevalent and costly chronic conditions. MACRA’s new payment system will also provide strong incentives to provide high quality care by paying bonuses for better results, and for innovations in care which keep diabetes under control. What strategies (e.g. clinical innovations, patient engagement strategies) are leading-edge organizations taking to improve care and control the costs of care for patients with the disease-the health plans and health systems that have high quality scores for diabetes care? What is and isn’t working?

    Jeff Dachis, CEO and Founder, One Drop
    Frank Westermann, Chief Executive Officer and Co-Founder, mySugr 
    Jose Peña, Chief Executive Officer and Chief Medical Officer, Rio Grande Valley ACO

    Moderator:Sarah Thomas, Managing Director, Deloitte Center for Health Solutions

  • 3:55pm
    Skills and Leadership for the New Health Economy: The Healthcare Workforce of the 21st Century

    From Chief Patient Officer to Health Coach to Physician Assistant and  beyond, roles and responsibilities in the healthcare system are evolving rapidly as new roles emerge, traditional professional boundaries converge, digital technologies take root and care moves from episodic to multi-disciplinary. What will the next generation healthcare workforce look like - how will the healthcare workforce be reshaped to fulfil the needs of the new health economy? Is the education system preparing the right type of graduates for the future? What will be the impact of robotics and artificial intelligence? Will robotics and automation do away with specific healthcare jobs?

    Joseph Damore, Vice President, Population Health Management, Premier
    Alyse Forcellina, Leader, US Healthcare Practice, Egon Zehnder
    Julie Staudenmier, Senior Director Global Learning and Development, Pfizer
    Janet Vergis, Former CEO, OraPharma; Executive Advisor to private equity 

    Moderator: Sarah Neville, Global Pharmaceuticals Editor, Financial Times

  • 4:35pm
    Beyond Genomics: Harnessing Innovation on the Frontiers of Science and Technology

    Healthcare is in the throes of a fast paced science and technology revolution. Individualized medicine, gene therapies, the microbiome, drone technology and advanced robotics are just some of the advanced technologies coming increasingly to the fore. This concluding session of the Summit will review the leading edge technologies advancing in the labs with the potential to transform health and personal care in the years ahead. Critical issues to include the ability of society to pay for such innovations will also be addressed by our panel of leading scientists, innovators and investors.

    Jeff Marrazzo, Co-Founder and CEO, Spark Therapeutics
    Jason Park, Principal, Flagship Pioneering
    Jeffrey Riley, Chief Executive Officer, President and Director, Synthetic Biologics
    Adam Pellegrini,  Vice President of Digital Health, Fitbit

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 5:15pm
    Closing Remarks from the Chair

Why Attend?

  • Gain insights into the next stage of reform and how the future of healthcare in the US will unfold.
  • Keep abreast of the next big thing in healthcare-tackling the social determinants of health.
  • Review the diverse strategies leading-edge companies are adopting to manage the cost and improve outcomes of diabetes care.
  • Understand the game-changing implications for payers, providers, and patients of MACRA and the accelerating transition from fee-for-service to value based care.
  • Don’t get left behind - be part of a must-attend event mapping the continuing transformation of healthcare.

Who Attends?

This event is for: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Head Doctors, Heads of R&D, Emerging Markets, Consumer Health, Government Relations, Pricing, Regulation, Market Access, etc. and other senior-level executives in the following sectors:

  • Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies, Pharmacies
  • Medical Devices and Diagnostics
  • Investment (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups, Health Insurance, Investment Banks)
  • Legal Counsel
  • Healthcare IT (Patient records, data, mobile healthcare applications, social media)
  • Regulation
  • Hospitals, Physician Networks, Healthcare providers
  • Government payers and Government agencies

With the support of (1)

About Life Sciences and Health Care at Deloitte*

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information, visit or email

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Lead sponsor (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. For further information please visit  Follow @iconplc on Twitter.

Associate Sponsors (2)

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 29,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

 Innovation used to be the domain of R&D leaders, entrepreneurs and consultants, all chasing the next big thing. Today, with competition emerging from all corners—startups, legacy competitors, and even technology companies hungry for new markets—that former notion of innovation can no longer apply.
To succeed and survive today, healthcare CEOs and boards need to become masters of innovation, able to empower their people to unlock the best ideas, and then bring the best solutions to market.
At Egon Zehnder, we work with many of the world’s leading organizations to help them define and recruit the leadership teams need to succeed in today’s age of innovation and disruption. Through our partnership with Harvard Business School professor Linda A. Hill—a renowned expert on commercial innovation—we have developed the Innovation Quotient, a framework proven to help leaders catalyze the creativity necessary for their organization’s success.
Different from the traditional visionary qualities of leadership, innovative leaders are able to set in motion creative abrasion, agility and resolution that has been shown to lead to unexpected breakthroughs. Managing this process requires a unique set of leadership skills, including the ability to unleash the energy of the enterprise while also harnessing that power to meet concrete milestones and objectives.
We look forward to sharing our knowledge, and learning how your healthcare organization is innovating and competing in the face of constant disruption.

Breakfast briefing (1)

Diaceutics is a global group of experts from the laboratory, diagnostic and pharmaceutical industries. Bio: Our goal is to help pharmaceutical companies integrate diagnostic testing into their treatment pathways. We are empowered through a real-time flow of testing data from our worldwide laboratory network which we use to help our pharma clients understand and leverage the diagnostic landscape.

Diaceutics combines deep domain expertise with hands-on experience from over 200 diagnostic projects. Our digitally-enabled, proprietary Diaceutics Method® helps pharma companies master diagnostic launches and deliver a superior return on the diagnostic strategy. This is achieved by leveraging unique real-time lab analytics to ensure companies can segment their target physicians by testing behaviours. Diagnostic launches are implemented via our global lab network, providing pharma with rapid launches in the world’s top 10 markets.

Luncheon Keynote Sponsor (1)

Biopharmaceutical innovation is advancing faster than ever before, and we need to make sure we have a payment and reimbursement system that is as innovative as the medicines. That is why the biopharmaceutical industry launched The Value Collaborative to bring researchers, caregivers, patients, payers and policymakers together to advance solutions that will enable the private sector to lead the move toward a value driven health care system.

Supporting Partner (3)

FT Health
The essential briefing for decision makers in health

FT Health is a weekly guide to the news and analysis that matters for decision makers in government, healthcare, research, industry and policy-making around the world. Leading specialists curate the best articles from the FT and across the web and make the links between the big issues. FT Health signposts important coverage on topics including infectious and non-communicable disease, public health, healthcare policy and practice, public health, research, development, drugs, vaccines and diagnostics. Straight to your inbox every Friday.

StartUp Health is on a 25-year mission to collaborate with entrepreneurs to improve the health and wellbeing of everyone in the world. StartUp Health believes that something magical happens when you bring together coachable entrepreneurs from around the world who have the mindset to achieve health moonshots. Since 2011, StartUp Health has been investing in a global army of entrepreneurs -- called Health Transformers® -- to achieve Health Moonshots: Access to Care, Cost to Zero, Cure Disease, End to Cancer, Women’s Health, Children’s Health, Nutrition & Fitness, Brain Health, Mental Health & Happiness, Longevity, and End Addiction.

Backed by Advocate Aurora Health, Chiesi Group, Steve Case, Mark Cuban, Esther Dyson, Brad Feld, GuideWell, Jason Finger, Jerry Levin, Kaiser Permanente Ventures, Masimo, Novartis, Otsuka, and Ping An Group, StartUp Health has the world’s largest digital health portfolio with more than 250 companies spanning six continents and 21 countries. Learn more at

The International Lawyers Network is an association of 91 high-quality, full-service law firms with over 5,000 lawyers worldwide. The Network provides clients with easily accessible legal services in 67 countries on six continents.

Nearby Accommodation

We have put together a unique Hotel Map that shows hotel deals close to the event venue. To view, click here



Convene Conference Center
730 Third Avenue
NY 10017
New York

United States of America

Tel: (973) 907-4928



Tim Powell
Sponsorship Opportunities
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Chandni Saberwal
Marketing, Media Partner & Press Inquiries
Financial Times
Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times